Showing results (171-180 of 584) with videos related to
Sort By:
Pageof 59
JTO Clinical and Research Reports|September 30, 2021
Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief ReportDiego Enrico, Ludovic Lacroix, Jeanne Chen, et al.European Journal of Cancer (Oxford, England : 1990)|March 14, 2022
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMAJordi Remon, Benjamin Lacas, Roy Herbst, et al.Critical Reviews in Oncology/Hematology|August 2, 2022
Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic reviewDaniele Presti, Filippo Gustavo Dall'Olio, Benjamin Besse, et al.Plos Computational Biology|June 17, 2025
Multimodal CustOmics: A unified and interpretable multi-task deep learning framework for multimodal integrative data analysis in oncologyHakim Benkirane, Maria Vakalopoulou, David Planchard, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLCStéphane Champiat, Ecaterina Ileana, Giuseppe Giaccone, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 23, 2014
Dendritic cell-derived exosomes as immunotherapies in the fight against cancerJonathan M Pitt, Mélinda Charrier, Sophie Viaud, et al.Nature Reviews. Clinical Oncology|October 27, 2018
Hyperprogressive disease: recognizing a novel pattern to improve patient managementStéphane Champiat, Roberto Ferrara, Christophe Massard, et al.Investigational New Drugs|April 4, 2009
Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case reportAndrea Gombos, Hassan Izzedine, Benjamin Besse, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2018
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung CancerKathryn C Arbour, Laura Mezquita, Niamh Long, et al.JAMA Oncology|January 13, 2018
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung CancerLaura Mezquita, Edouard Auclin, Roberto Ferrara, et al.Pageof 59